Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DX-8951f in Hormone-Refractory Prostate Cancer
NCT00004045Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 1999
- Primary completion
- Aug 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exatecan in prostate cancer (PCa), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Antitumor activity as measured by PSA response. Started Jun 1999; status: completed.
02
Drugs
exatecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00004045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004045.